Drug Profile
Influenza A virus H1N1 vaccine (CSL 425) - CSL Biotherapies
Alternative Names: CSL 425; CSL monovalent H1N1 influenza virus vaccine (CSL425); Inactivated H1N1 vaccine (unadjuvanted) - CSL; Influenza A/H1N1 2009 vaccine; Panvax H1N1; Swine flu vaccine - CSLLatest Information Update: 04 Jun 2010
Price :
$50
*
At a glance
- Originator CSL
- Class Antivirals; Influenza A virus H1N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Influenza A virus H1N1 subtype
Most Recent Events
- 22 May 2010 CSL completes the phase II CSLCT-CAL-09-60 trial in the prevention of Influenza-A virus H1N1 subtype infections in healthy children in USA
- 22 May 2010 CSL completes the phase II CSLCT-CAL-09-59 trial in the prevention of Influenza-A virus H1N1 subtype infections in healthy adults in Australia
- 22 Dec 2009 Efficacy and adverse events data from a phase II trial in Influenza-A virus H1N1 subtype released by CSL